Paradigm Health has launched a research collaboration with the United States Food and Drug Administration to test a real-time model for clinical trial data review using its Study Conduct platform. The initiative is being implemented in an AstraZeneca-sponsored Phase 2 trial and an Amgen-sponsored Phase 1b trial, placing automated data capture, regulatory signal reporting and FDA-facing data interoperability at the centre of a broader push to modernize clinical development.
Why Paradigm Health’s FDA collaboration matters for the future of clinical trial execution
The most important point is not simply that Paradigm Health has secured a high-profile regulatory collaboration. The more meaningful development is that the model targets one of the least glamorous, yet most expensive, bottlenecks in drug development: the slow movement of clinical data from trial sites to sponsors and then to regulators. If real-time clinical trial data review can work safely, sponsors may eventually spend less time waiting for cleaned, reconciled and repackaged datasets before regulators can assess emerging safety or efficacy signals.
That is why this collaboration lands at a sensitive moment for the U.S. clinical research ecosystem. Clinical trials have become more complex, more distributed and more data-heavy, while regulators, sponsors and trial sites remain tied to workflows that often depend on manual entry, duplicative monitoring and delayed reporting cycles. Paradigm Health’s model tries to compress that timeline by capturing data from electronic health records and other structured and unstructured sources, applying predefined reporting logic, and transmitting only the data points relevant to regulatory review.
The risk is that speed is not automatically the same thing as regulatory readiness. Clinical trial data must be traceable, auditable, validated and interpretable in context. If a real-time platform surfaces signals too aggressively, sponsors and regulators could face noise, false alarms or inconsistent data interpretation. If it filters too narrowly, important clinical nuance may be missed. The central test is whether Paradigm Health can prove that automation improves regulatory visibility without weakening evidentiary quality.
How real-time FDA review could reduce one of drug development’s least visible bottlenecks
Clinical development is often discussed through the lens of trial endpoints, enrolment rates and regulatory submissions. However, the operational burden between patient visit and regulatory decision is just as important. Data must be entered, cleaned, monitored, queried, reconciled and converted into formats that can support review. That process can stretch for months, particularly in oncology, rare disease and early-stage development settings where safety signals can be complex and site-level data quality varies.
Paradigm Health’s Study Conduct platform is designed to attack that middle layer. By pulling information directly from electronic health records and other data sources, the platform aims to reduce manual data entry and monitoring burden while allowing sponsors and the FDA to receive defined safety and efficacy signals much earlier. For trial sponsors, that could mean faster operational decision-making. For regulators, it could mean a more continuous view of trial evolution rather than a periodic view shaped by formal submissions.
However, the model will need to prove that automation does not merely shift work from one part of the system to another. Trial sites may still need to validate data capture, sponsors may still need to manage protocol deviations and regulators may still need to understand how algorithmically generated signals were defined. The platform’s value will depend on whether it simplifies the workflow across the full trial chain, not just whether it accelerates the transfer of selected data fields.
Why Amgen and AstraZeneca make this pilot more than a small technology experiment
The involvement of Amgen Inc. and AstraZeneca PLC gives the collaboration greater strategic weight. These are not marginal sponsors testing a niche workflow in isolation. They are large pharmaceutical companies with extensive clinical development infrastructure, regulatory experience and global trial portfolios. Their participation suggests that real-time trial review is being explored not only as a technology upgrade, but as a potential operating model for mainstream drug development.
The AstraZeneca-sponsored Phase 2 trial includes sites such as The University of Texas MD Anderson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania, which matters because leading academic centres often operate in data-rich but operationally complex environments. If the platform can function across major research institutions, it may offer a more credible template for adoption beyond a tightly controlled pilot. The Amgen-sponsored Phase 1b trial adds another layer because early-stage trials can be especially sensitive to rapid safety assessment and dose-related interpretation.
The limitation is that two trials cannot establish a universal model. A workflow that performs well in selected oncology trials may not automatically translate to large cardiovascular studies, decentralized trials, rare disease programs, vaccine trials or post-market evidence generation. Industry observers are likely to watch whether the platform can handle different endpoints, different data sources, different site capabilities and different levels of trial complexity before treating the model as scalable.
What this reveals about the FDA’s shift toward continuous regulatory oversight
The collaboration fits into a broader regulatory direction: moving from episodic review toward more continuous, data-enabled oversight. The FDA has already been placing greater emphasis on real-world data, electronic health records, digital health technologies and advanced analytics in drug and device development. Paradigm Health’s collaboration sits at the intersection of those themes because it uses technology not simply to collect more data, but to change when and how regulators can see relevant trial information.
That shift could be significant for sponsors. A more continuous review environment may reduce the lag between emerging evidence and regulatory interpretation. In theory, regulators could identify safety concerns, efficacy trends or data integrity issues earlier, while sponsors could avoid late-cycle surprises. For patients, the upside is that promising therapies could move through development more efficiently if trial evidence is available in cleaner and more timely form.
The unresolved question is how far continuous oversight can go without blurring responsibilities. Sponsors remain responsible for trial conduct and data integrity. Regulators must remain independent reviewers rather than operational co-managers of ongoing studies. Real-time data visibility could improve review efficiency, but it also raises questions about when regulators should intervene, how preliminary signals should be interpreted and how sponsors should document decisions made during a continuously monitored trial.
Why electronic health record integration is powerful but difficult to standardize
Electronic health record integration is one of the most attractive elements of the Paradigm Health model because it targets a long-standing inefficiency in clinical research. Much of the data needed for trials already exists somewhere in the care environment, yet trial teams often duplicate data entry into separate electronic data capture systems. If data can be extracted, mapped and validated more directly, clinical research could become less burdensome for sites and more accessible to health systems that lack large research administration teams.
That matters for trial access. Smaller and community-based providers often struggle to participate in complex trials because the operational load is too high. A platform that reduces data entry, monitoring burden and reporting complexity could expand where clinical research can be conducted. For sponsors trying to improve enrolment diversity and reach patients outside major academic centres, that could become a major advantage.
The problem is that electronic health records are messy. Data structures differ across health systems, clinical notes may be unstructured, coding practices vary and missing data can be common. Algorithmic extraction can help, but it must be validated repeatedly against clinical reality. Regulators will need confidence not only that data are transmitted quickly, but that the data represent the right clinical events, the right timing and the right patient context.
What sponsors and CROs should watch as real-time regulatory review develops
For pharmaceutical sponsors and contract research organizations, the collaboration raises both opportunity and disruption. If real-time regulatory review gains traction, sponsors may need to rethink how trial operations, data management, safety monitoring and regulatory affairs work together. Traditional handoffs between clinical operations, biostatistics, medical monitoring and regulatory submission teams may become less sequential and more integrated.
That could create pressure on existing clinical trial infrastructure providers. Electronic data capture vendors, clinical research organizations, safety systems, real-world data platforms and regulatory technology providers may all need to adapt if sponsors begin asking for workflows that support continuous regulatory signal transmission. Paradigm Health’s advantage is that it is positioning its platform as infrastructure rather than just software. The more strategic question is whether sponsors will see this as a replacement for existing trial workflows or as an added layer that must integrate with them.
Adoption will depend on proof that the model lowers total burden. If sponsors must maintain conventional systems while also supporting real-time FDA reporting, the business case weakens. If the model reduces monitoring costs, improves site participation, shortens review cycles and avoids rework, the commercial case becomes much stronger. The pilot’s outcome will therefore be judged not only by regulatory enthusiasm, but by measurable operational savings.
Why patient privacy and data minimization will remain central to adoption
Paradigm Health has emphasized that the platform transmits only critical signals and data needed for regulatory determinations, while protecting patient privacy and minimizing unnecessary dataset transfer. That is a crucial design choice. Real-time regulatory review would be far harder to scale if it required regulators to receive broad raw patient records from trial sites. A signal-based model may offer a more practical balance between visibility and privacy.
For regulators, data minimization can make the model easier to defend. For sponsors, it may reduce concerns about excessive data exposure. For trial sites, it may make participation less intimidating than a model built around large-scale raw data transfer. This is especially important in oncology and early-stage research, where sensitive clinical information, genomic data, imaging results and longitudinal treatment records may be involved.
Still, privacy protection does not remove the need for transparency. Sponsors and regulators must understand how the platform defines critical events, how data are transformed, how errors are detected and how audit trails are preserved. If the system becomes a black box, adoption will slow. The next phase must show that privacy, speed and explainability can coexist in a regulatory-grade environment.
Paradigm Health’s FDA collaboration is promising, but validation will decide its importance
The expert view is that Paradigm Health’s FDA collaboration is potentially important because it addresses a real structural weakness in clinical development rather than a cosmetic workflow problem. Trial data review has long been too slow, too fragmented and too dependent on retrospective packaging. A validated real-time model could improve safety visibility, reduce administrative drag and make U.S. trial execution more competitive.
However, this is still an infrastructure proof point, not a finished transformation. The collaboration must demonstrate that automated signal detection is accurate, that site workflows become easier rather than more complicated, and that regulators can act on real-time data without compromising review independence. It must also show that the model can move beyond carefully selected pilots into broader trial categories with different endpoints, patient populations and data environments.
The bigger industry message is clear. Clinical trial modernization is moving from discussion to implementation. Paradigm Health has placed itself in the middle of that shift, but the platform’s long-term relevance will depend on evidence. If the Amgen and AstraZeneca trials show that real-time review can be operationally reliable, auditable and clinically meaningful, this collaboration could become a template for the next generation of regulatory data infrastructure. If not, it will still serve as a useful stress test for how difficult it is to turn clinical trial automation into regulatory-grade practice.
Paradigm Health’s FDA collaboration puts clinical trial data automation under the spotlight added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →